

DAPAGLIFLOZIN tablets (Forxiga®) in combination with insulin for the treatment of Type 1 Diabetes Mellitus

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of DAPAGLIFLOZIN tablets (Forxiga®) in combination with insulin for the treatment of Type 1 Diabetes Mellitus

GREY

Dapagliflozin (Forxiga®) has recently been granted a license extension and is now indicated for the treatment of insufficiently controlled type 1 diabetes mellitus in adults as an adjunct to insulin in patients with BMI $\geq 27\text{kg/m}^2$, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.¹

This recommendation will be reviewed when the NICE TA is published. This is expected to be in August 2019.

In the meantime, clinicians should continue to follow national guidance and prescribe local formulary choices for the treatment of type 1 diabetes mellitus in adults:

- > NICE Guideline [NG17 Type 1 diabetes in adults: diagnosis and management](#) (updated July 2016)
- > Pan Mersey Formulary - [Drugs used in diabetes](#)

References

1. AstraZeneca UK Limited. Summary of Product Characteristics: [Forxiga 5 mg film-coated tablets](#), 20 March 2019. Accessed online 05 April 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.